NasdaqCM:SLS

Stock Analysis Report

Executive Summary

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has SELLAS Life Sciences Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SLS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.6%

SLS

4.7%

US Biotechs

7.2%

US Market


1 Year Return

-96.4%

SLS

1.8%

US Biotechs

-10.4%

US Market

Return vs Industry: SLS underperformed the US Biotechs industry which returned -0.7% over the past year.

Return vs Market: SLS underperformed the US Market which returned -12.7% over the past year.


Shareholder returns

SLSIndustryMarket
7 Day10.6%4.7%7.2%
30 Day-9.6%-3.5%-12.6%
90 Day-56.3%-5.4%-19.4%
1 Year-96.4%-96.4%2.6%1.8%-8.5%-10.4%
3 Yearn/a14.0%11.1%15.8%8.3%
5 Yearn/a-3.6%-7.9%35.8%21.0%

Price Volatility Vs. Market

How volatile is SELLAS Life Sciences Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SELLAS Life Sciences Group undervalued compared to its fair value and its price relative to the market?

1.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SLS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SLS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SLS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SLS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SLS is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is SELLAS Life Sciences Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

54.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SLS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SLS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SLS's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SLS's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has SELLAS Life Sciences Group performed over the past 5 years?

-23.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SLS is currently unprofitable.

Growing Profit Margin: SLS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLS is unprofitable, and losses have increased over the past 5 years at a rate of -23.5% per year.

Accelerating Growth: Unable to compare SLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SLS has a negative Return on Equity (-316.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is SELLAS Life Sciences Group's financial position?


Financial Position Analysis

Short Term Liabilities: SLS's short term assets ($8.2M) exceed its short term liabilities ($5.3M).

Long Term Liabilities: SLS's short term assets ($8.2M) exceed its long term liabilities ($5.2M).


Debt to Equity History and Analysis

Debt Level: SLS is debt free.

Reducing Debt: SLS had no debt 5 years ago.


Balance Sheet

Inventory Level: SLS has a low level of unsold assets or inventory.

Debt Coverage by Assets: SLS's debt is not covered by short term assets (assets are -294.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SLS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -25% each year


Next Steps

Dividend

What is SELLAS Life Sciences Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SLS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Angelos Stergiou

8.17s

Tenure

US$1,240,307

Compensation

Dr. Angelos M. Stergiou, MD, ScD h.c., is the Founder, President and Chief Executive Officer of SELLAS Life Sciences Group AG (formerly, Sellas Inc.). Dr. Stergiou served as Vice President of Clinical Dev ...


CEO Compensation Analysis

Compensation vs Market: Angelos's total compensation ($USD1.24M) is above average for companies of similar size in the US market ($USD605.16K).

Compensation vs Earnings: Angelos's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Angelos Stergiou
Founder8.17yrsUS$1.24m0.13% $16.0k
Barbara Wood
Executive VP2yrsUS$630.68kno data
Nicholas Sarlis
Chief Medical Officer0.75yrUS$783.30kno data
John Burns
VP of Finance & Corporate Controller & Interim Principal Accounting Officerno datano data0.000010% $1.3
Martin Baum
Chief Operating Officer3.42yrsno datano data
Dragan Cicic
Senior VP of Clinical Developmentno datano datano data
Christopher Shackleton
Director of Clinical and Business Operationsno datano datano data
Jörg Breitkopf
Head of Clinical Operationsno datano datano data
David Moser
Vice President of Legal Affairsno datano datano data

2.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: SLS's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Angelos Stergiou
Founder8.17yrsUS$1.24m0.13% $16.0k
Robert Van Nostrand
Directorno dataUS$122.63kno data
John Varian
Directorno dataUS$124.00kno data
David Scheinberg
Directorno dataUS$156.88kno data
Jane Wasman
Chairman3.17yrsUS$138.75kno data
Jedd Wolchok
Member of Scientific Advisory Board4.33yrsno datano data
Jeffrey Weber
Chairman of Scientific Advisory Board1.75yrsno datano data
Alexander Maximiliaan Eggermont
Member of Scientific Advisory Board3.33yrsno datano data
Sattva Neelapu
Member of Scientific Advisory Boardno datano datano data
Larry Kwak
Member of Scientific Advisory Board4.33yrsno datano data

3.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: SLS's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 878.3%.


Top Shareholders

Company Information

SELLAS Life Sciences Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SELLAS Life Sciences Group, Inc.
  • Ticker: SLS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$12.630m
  • Shares outstanding: 6.72m
  • Website: https://www.sellaslifesciences.com

Number of Employees


Location

  • SELLAS Life Sciences Group, Inc.
  • 15 West 38th Street
  • 10th Floor
  • New York
  • New York
  • 10018
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RXK3DB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2018
SLSNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJan 2018

Biography

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 03:54
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.